WO2024097704A1 - Formulation à base de plantes pour améliorer la croissance de la peau - Google Patents

Formulation à base de plantes pour améliorer la croissance de la peau Download PDF

Info

Publication number
WO2024097704A1
WO2024097704A1 PCT/US2023/078280 US2023078280W WO2024097704A1 WO 2024097704 A1 WO2024097704 A1 WO 2024097704A1 US 2023078280 W US2023078280 W US 2023078280W WO 2024097704 A1 WO2024097704 A1 WO 2024097704A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
collagen
marine
proteoglycans
skin
Prior art date
Application number
PCT/US2023/078280
Other languages
English (en)
Inventor
John Alkire
Original Assignee
Zanda, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zanda, Llc filed Critical Zanda, Llc
Publication of WO2024097704A1 publication Critical patent/WO2024097704A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a nutritional supplement composition
  • a nutritional supplement composition comprising marine proteoglycans and collagen that can be administered to a human subject to stimulate skin cell growth.
  • the nutritional supplement can be administered in an oral form or as a topical agent.
  • the present invention relates to methods of stimulating or promoting skin cell growth in the face or any selected areas of the body. More specifically, the method comprises administering the nutritional supplement composition to a human subject in order to stimulate or promote skin cell growth.
  • Skin is composed of the epidermis and the dermis. Below these layers lies the hypodermis, which is not usually classified as a layer of skin.
  • the hypodermis is also commonly referred to as subcutaneous fat layer, or subcutaneous tissue.
  • the outermost epidermis is made up of stratified squamous epithelium with an underlying basement membrane. It contains no blood vessels and is nourished by diffusion from the dermis.
  • the main type of cells which make up the epidermis are keratinocytes, with melanocytes and langerhans cells also present. This layer of skin is responsible for keeping w ater in the body and keeping other harmful chemicals and pathogens out.
  • the dermis lies below the epidermis and contains a number of structures including blood vessels, nerves, hair follicles, smooth muscle, glands and lymphatic tissue.
  • the dermis (or corium) is typically 3-5 mm thick and is the major component of human skin. It is composed of a network of connective tissue, predominantly collagen fibrils providing support and elastic tissue providing flexibility.
  • the main cell types are fibroblasts, adipocytes (fat storage) and macrophages.
  • the hypodermis lies below the dermis. Its purpose is to attach the skin to underlying bone and muscle as well as supplying it with blood vessels and nerves. It is made up of loose connective tissue and elastin.
  • the main cell types are fibroblasts, macrophages and adipocytes.
  • the hypodermis contains 50% body fat. Fat serves as padding and insulation for the body.
  • Skin aging occurs as the result of several factors: inherent changes within the skin, effects of gravity, facial muscles acting on the skin (dynamic lines), soft tissue loss or shift and bone loss and loss of tissue elasticity’.
  • the skin ages when the epidermis begins to thin, causing the junction with the dermis to flatten. Collagen decreases as a person ages and the bundles of collagen, which gives the skin turgor, become looser and lose strength. When the skin loses elasticity, it is less able to resist stretching. Coupled with gravity, muscle pull and tissue changes, the skin begin to wrinkle. Loss of skin cells and loss of bonds between cells also reduces the barrier function of the skin, w hich can cause the skin's pore size to increase.
  • the present invention is a nutritional supplement. It is a novel composition comprising marine proteoglycans and collagen, which stimulates the growth of skin cells.
  • a particular embodiment of the present disclosure relates to an oral nutritional supplement that includes the novel composition.
  • the composition may be delivered as non-toxic salts thereof, effective complexes thereof, stable chelates thereof, active esters thereof, functional derivatives thereof, and mixtures thereof which are effective to stimulate skin cell growth in the general population.
  • a topical nutritional supplement that comprises a mixture of marine proteoglycans and type I collagen.
  • the type I collagen is bovine, porcine, or marine collagen.
  • Methods of stimulating skin cell growth comprise administering the novel composition to a human subject.
  • composition will find applications to stimulate skin cell growth and to promote skin tissue growth, repair the skin, or to rebalance skin proliferation.
  • the nutritional supplement includes a composition for promoting skin cell growth comprising marine proteoglycans (obtained from fish cartilage) and collagen in a ratio of 0.1% to 10% marine proteoglycans to 90% to 99.9% collagen.
  • the composition comprises marine proteoglycans and collagen in a ration of 0.1% to 99.9%.
  • the composition comprises marine proteoglycans and collagen in a ration of 10% to 90%.
  • the collagen may be type I collagen and, more specifically, can be bovine collagen.
  • a method of promoting skin cell grow th comprises administering the nutritional supplement to a human subject.
  • the nutritional supplement may be administered from one to three times daily or. alternatively, may be administered every other day, or may be administered once a week.
  • the nutritional supplement may be administered on an empty stomach.
  • the composition may be administered topically on the skin.
  • the nutritional supplement of the third embodiments is essentially limited to the aforementioned ingredients and does not include any additional active ingredients intended to add nutritional content (e.g., vitamins, minerals, etc.), but may include additional ingredients not intended to add nutritional content such as ingredients intended to fulfill a non-nutritional purpose (e.g., coloring, fillers, flavoring, an ingredient for maintaining the structural form, etc.).
  • additional active ingredients intended to add nutritional content
  • additional ingredients not intended to add nutritional content such as ingredients intended to fulfill a non-nutritional purpose (e.g., coloring, fillers, flavoring, an ingredient for maintaining the structural form, etc.).
  • Each ingredient of the nutritional supplement of the present invention may be prepared in accordance with any method known to one of ordinary skill in the art. Alternatively, each ingredient may be obtained in a fully prepared from a commercially available source.
  • the nutritional supplement of the present invention may be in any suitable oral administration form, including but not limited to: a chewable form, a liquid form, a spray form, a capsule form, a suppository form, dissolvable wafer, and a powder form.
  • the ingredients of the nutritional supplement may be distributed homogeneously or non-homogeneously within the nutritional supplement.
  • the nutritional supplement of the present invention may be ingested on a regular basis, such as a daily or weekly intake at a dosage tailored to an individual's needs; i.e., the nutritional supplement is to be taken regularly as multiples (l x, 2x, etc.) of the structural units (pills, tablets, capsules, liquid dose, etc.) in accordance with the needs of the individual.
  • the nutritional supplement of the present invention may be ingested on an as-needed basis at a dosage tailored to the individual's needs. Medical or nutritional counseling may be beneficial for arriving at a desirable or optimal dosage tailored to the individual's needs. Topical delivery systems such as lotions and creams may apply.
  • test products were tested on their solubility in cell culture media or DMSO (in that order). Starting from doses of 200 mg/mL the test products were diluted stepwise until totally solved. Since no effect of the test product at concentrations w ere expected below 2 mg/mL we did not dilute further than that regardless if fully dissolved or not. Test products that did not dissolve in DMSO at a concentration of 2 mg/mL were tested in cell culture media in a suspension of 2 mg/mL. Marine proteoglycans samples demonstrated a maximum solubility concentration of 100 mg/ml. Type I (bovine) collagen samples demonstrated a maximum solubility concentration of 20 mg/ml.
  • Marine proteoglycans samples were tested at concentrations ranging from 0.01 to 100 mg/ml. The highest concentration with more than 70% viability was 0.01 mg/ml.
  • Type I collagen samples were tested at concentrations ranging from 0.2 to 20 mg/ml. The highest concentrarion w ith more than 70% viability 7 was 20 mg/ml and was nontoxic at all tested concentrations.
  • Keratinocytes were seeded in 3000 cells/well onto 96-well plates and were treated with a dose of the test product causing no loss of viability 7 greater than 90% as evalutated in 2.2. 24h after seeding.
  • the cells were cultured for a maximum of 72 hours to cover more than 70% (up to 90%) of the total growth area. This was done to prevent slowing down of proliferation due to contact inhibition effects.
  • a second run was conducted (if necessary) due to toxic effects of combinations or other unexpected events.
  • Relative cell numbers at the end of the treatment again were determined by the addition of MTT. Results were generated by absorbance measurement of the blue metabolite formed. The results were presented in tabular form including mean, standard deviation and significance of differences (if applicable).
  • Marine proteoglycans applied at a concentration of 0.01 mg/ml resulted in a mean value of 99.5% proliferation of skin cells relative to the control when measured at 72 hours.
  • Type I collagen applied at a concentration of 6 mg/ml resulted in a mean value of 102.7% proliferation of skin cells relative to the control with a mean P value of 0.05 when measured at 72 hours.
  • the application of the combined type I collagen/marine proteoglycans applied at a respective concentration of 6mg/0.01mg resulted in a mean value of 134.3% proliferation of skin cells with a P value of 0.001 relative to the control when measured at 72 hours.
  • the latter represents a P value that is 50 times more significant.
  • the application of the combined type I collagen/marine proteoglycans applied at a respective concentration of 0.3mg/0.01mg resulted in a mean value of 132% proliferation of skin cells with a P value of 0.001 relative to the control when measured at 72 hours, with the same significant P value.
  • the application of the combined type I collagen/marine proteoglycans applied at a respective concentration of O.lmg/O.Olmg resulted in a mean value of 128% proliferation of skin cells with a P value of 0.01 relative to the control when measured at 72 hours, representing a P value that is 10 times more significant.
  • the immortal cell line HaCat which is a keratinocyte derived cell line.
  • the cell line is stable, not of carcinogenic origin and retains many properties of normal keratinocytes.
  • Tissue Model The testing determines how exposure to the test materials ⁇ TMs) will influence mRNA expression in in vitro cell tissue samples. Changes in genes will be expressed relative to a suitable Vehicle Controls alone and in mixtures.
  • the study is performed using full -thickness EFT-400 in vitro skin tissues comprised of normal human keratinocytes in a stratified comeal layer, and a dermal component containing an intact dermal-epidermal junction (DEJ) and viable fibroblasts.
  • EFT-400 in vitro skin tissues comprised of normal human keratinocytes in a stratified comeal layer, and a dermal component containing an intact dermal-epidermal junction (DEJ) and viable fibroblasts.
  • DEJ dermal-epidermal junction
  • RNASeq Differential Gene Expression ⁇ RNASeq
  • the analysis is performed using an Illumina NextSeq 550 Dx instrument. A read depth of 25M reads per sample. Data analysis is performed to identify statistically significant changes in gene expression.
  • the results will show thousands of skin gene marker expressions at ranges from 1% to 10% marine proteoglycans to 90 % to 99% collagen, several of which are significant to skin growth.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne une composition comprenant des protéoglycanes marins et du collagène, stimulant la croissance des cellules de la peau. Des procédés de stimulation de la croissance de cellules de la peau comprennent l'administration de la nouvelle composition à un sujet humain.
PCT/US2023/078280 2022-11-02 2023-10-31 Formulation à base de plantes pour améliorer la croissance de la peau WO2024097704A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263421910P 2022-11-02 2022-11-02
US63/421,910 2022-11-02

Publications (1)

Publication Number Publication Date
WO2024097704A1 true WO2024097704A1 (fr) 2024-05-10

Family

ID=90931468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/078280 WO2024097704A1 (fr) 2022-11-02 2023-10-31 Formulation à base de plantes pour améliorer la croissance de la peau

Country Status (1)

Country Link
WO (1) WO2024097704A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06179612A (ja) * 1992-07-27 1994-06-28 Nonogawa Shoji Kk 化粧料
US20130310540A1 (en) * 2011-01-19 2013-11-21 Sunstar Inc. Extract of aquatic animal cartilage
US20140080761A1 (en) * 2009-07-16 2014-03-20 Hirosaki University Proteoglycan-containing material
WO2015083630A1 (fr) * 2013-12-04 2015-06-11 サントリーホールディングス株式会社 Composition contenant un peptide de collagène, un peptide d'élastine et un protéoglycane
KR20210039636A (ko) * 2019-10-02 2021-04-12 휴젤(주) 피부 보습용 화장료 조성물 및 이의 제조방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06179612A (ja) * 1992-07-27 1994-06-28 Nonogawa Shoji Kk 化粧料
US20140080761A1 (en) * 2009-07-16 2014-03-20 Hirosaki University Proteoglycan-containing material
US20130310540A1 (en) * 2011-01-19 2013-11-21 Sunstar Inc. Extract of aquatic animal cartilage
WO2015083630A1 (fr) * 2013-12-04 2015-06-11 サントリーホールディングス株式会社 Composition contenant un peptide de collagène, un peptide d'élastine et un protéoglycane
KR20210039636A (ko) * 2019-10-02 2021-04-12 휴젤(주) 피부 보습용 화장료 조성물 및 이의 제조방법

Similar Documents

Publication Publication Date Title
EP1021161B1 (fr) Utilisation de l'acide ellagique et de ses derives en cosmetique et en dermatologie
JP6215364B2 (ja) ＭＣ−１Ｒ、ＭＣ−２Ｒ、およびμオピオイド受容体調節
EP3288531B1 (fr) Methode d'amelioration de la sante de la peau et compositions pour
JP3706615B2 (ja) 肌のしわ予防及び低減のための組成物
US8747815B2 (en) Use of a cosmetic of pharmaceutical composition, comprising a lupeol-rich extract as an active ingredient for stimulating the synthesis of heat shock proteins
EP3335693B1 (fr) Composition pour usage externe
BRPI0905408A2 (pt) uso cosmético de pelo menos um monossacarìdeo, composição, e, dispositivo
AU2018255294A1 (en) Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout
KR20060089898A (ko) Ｅｇｃｇ와 장미 추출물을 함유하는 피부 외용제 조성물
KR20120095296A (ko) 피부톤 개선 또는 피부 탄력 증진용 화장료 조성물
US20130224318A1 (en) Use of CPT-1 Modulators and Compositions Thereof
WO2024045952A1 (fr) Composition contenant du collagène recombinant ayant des effets de réparation et apaisants, crème oculaire la contenant, son procédé de préparation et son utilisation
KR102613845B1 (ko) 천연물 유래의 피부개선용 화장조성물
CN115400065A (zh) 一种具有保湿、抗皱、抗衰、舒缓、修复多功效的护肤品组合物及其应用
CN111803422A (zh) 一种控油组合物及其应用
ES2387129T3 (es) Composición que comprende un extracto de loto azul para el tratamiento de las mioclonías faciales incontrloladas
JP2009298752A (ja) 皮膚外用剤組成物
WO2024097704A1 (fr) Formulation à base de plantes pour améliorer la croissance de la peau
WO2015001891A1 (fr) Composition pour augmenter la production de collagène, pour augmenter la production d'élastine et/ou pour activer la migration des kératinocytes et son utilisation
WO2012052695A1 (fr) Composition cosmetique ou dermatologique comprenant un extrait d'angelique son utilisation pour l'hydratation et l'eclat
JP5855949B2 (ja) ケラチン産生促進剤、染毛用剤及びマニキュア用剤
KR101936686B1 (ko) 미세 버블을 함유하는 피부 외용제 조성물
CN116869855B (zh) 含有胶原蛋白的皮肤修护组合物
TANSATHIEN et al. Development of protein extracts-loaded nanocarriers combination with microspicules for transdermal delivery
JPH09263529A (ja) 表皮角質化促進剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23886897

Country of ref document: EP

Kind code of ref document: A1